HEALEY ALS Platform Trial Regimen I expands to 240 participants
Highlights:
- Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
- Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected...
Read more: HEALEY ALS Platform Trial Regimen I expands to 240 participants




